A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ATI-50002 Topical Solution Administered Twice-Daily for 28 Days in Adult Subjects With AU and AT
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Jun 2018
At a glance
- Drugs ATI 502 (Primary)
- Indications Alopecia areata
- Focus Pharmacokinetics
- Sponsors Aclaris Therapeutics
- 12 Jun 2018 Planned End Date changed from 5 Apr 2018 to 15 Jul 2018.
- 12 Jun 2018 Planned primary completion date changed from 5 Mar 2018 to 30 Jun 2018.
- 12 Jun 2018 Status changed from recruiting to active, no longer recruiting.